Dataset Information


Outcomes of stereotactic body radiotherapy 60?Gy in 8 fractions when prioritizing organs at risk for central and ultracentral lung tumors.



For stereotactic body radiotherapy (SBRT) to central (C) and ultracentral (UC) lung tumors, our provincial practice has been to prioritize organs at risk (OARs) constraints by compromising target volume coverage if needed. The objectives are to report the treatment's efficacy and safety.


We conducted a retrospective analysis of all provincial patients who underwent SBRT at 60Gy in 8 fractions to C and UC lung tumors, from 2013 to 2017.


Ninety-eight lesions were treated, 57 (58.2%) C and 41 (41.8%) UC. The median follow-up was 22.9?months (range 2.5-64.8?months). The 1- and 3-year local control (LC) was 97.8 and 84.5% respectively, with no differences between C and UC groups (p =?0.662). Fifty-three (54.1%) cases had optimal dose coverage (V60Gy ITV&PTV >?95%), 29 (29.6%) had compromised PTV coverage (V60Gy ITV >?95%/PTV ConclusionsSBRT at 60Gy in 8 fractions achieves high rates of LC with low risks of significant toxicities, even if target volume coverage is reduced to meet OARs constraints.

PROVIDER: S-EPMC7047404 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC8097956 | BioStudies
| S-EPMC8397670 | BioStudies
| S-EPMC5680781 | BioStudies
| S-EPMC5864687 | BioStudies
| S-EPMC7324702 | BioStudies
| S-EPMC7223476 | BioStudies
| S-EPMC6036380 | BioStudies
| S-EPMC5119818 | BioStudies
| S-EPMC7807641 | BioStudies
| S-EPMC5034438 | BioStudies